January 3, 2008 / 12:55 PM / in 10 years

Celgene takeover of Pharmion clears antitrust hurdle

Jan 3 (Reuters) - Celgene Corp (CELG.O) said its proposed $2.9 billion acquisition of Pharmion Corp PHRM.O cleared an antitrust hurdle.

The 30-day waiting period under the Hart-Scott-Rodino Act had expired without the U.S. Federal Trade Commission requesting additional information, the company said in a statement.

The companies expect the transaction to close in April. (Reporting by Sharangdhar Limaye in Bangalore; Editing by Deepak Kannan)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below